Recent Security Class Actions

Merck & Company Inc. Common Stock (new) (NYSE: MRK)

42 Days left to seek lead plaintiff status.

Company Name:Merck & Company Inc. Common Stock (new)
Stock Symbol:NYSE: MRK
Class Period Start:02/03/2022
Class Period End (inclusive):02/03/2025
Filing Deadline:04/14/2025

According to the complaint, defendants provided investors with material information concerning Merck's expected revenue of $11 billion from sales of Gardasil by 2030. Defendants' statements included, among other things, confidence in Merck's purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil's growth in China. The full truth finally emerged on February 4, 2025, when Merck announced it would no longer achieve the long-forecasted $11 billion in sales of Gardasil by 2030, as it would cease shipments of Gardasil to China "through at least midyear" to facilitate a "rapid reduction of inventory." Defendants claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had "not recovered to the level we had expected."

 

Merck & Company Inc. Common Stock (new) (NYSE: MRK) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.